HilleVax (HLVX)

• Market cap: $97.3M
• 1 day: 0.52%
• 5 days: 5.43%
• 1 month: 33.79%
• 3 months: -2.51%
• 6 months: 5.43%
• Year to date: -6.73%
• 1 year: -85.30%
• 5 years: -89.84%
• 10 years: -89.84%
• Sector: Healthcare
• Industry: Biotechnology

About: HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Employees: 14

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

113% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 15

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

21% more capital invested

Capital invested by funds: $73.5M [Q3] → $88.7M (+$15.2M) [Q4]

2.15% more ownership

Funds ownership: 83.85% [Q3] → 86.0% (+2.15%) [Q4]

4% less funds holding

Funds holding: 79 [Q3] → 76 (-3) [Q4]

23% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 13

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $2 3% upside
• Avg. target: $2 3% upside
• High target: $2 3% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

HC Wainwright & Co. Matthew Caufield 25% 1-year accuracy 17 / 68 met price target

3% upside $2

Neutral Reiterated

31 Mar 2025